# A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

> **NCT03092895** · PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 157 (actual)

## Conditions studied

- Advanced Primary Liver Cancer
- Advanced Biliary Tract Carcinoma

## Interventions

- **BIOLOGICAL:** SHR-1210
- **DRUG:** Apatinib
- **DRUG:** FOLFOX4
- **DRUG:** GEMOX

## Key facts

- **NCT ID:** NCT03092895
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-24
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03092895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03092895, "A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03092895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*